Scientists hunt for clues to predict lung cancer drug success
NCT ID NCT04312308
First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study aimed to find biological markers in the blood and tumors that could predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug atezolizumab. Researchers analyzed immune cells, genetics, and microbiomes from 100 participants. The goal was to improve treatment decisions by identifying who would benefit most from this therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.